Sermorelin vs Ipamorelin: How the Two Compare

Sermorelin and ipamorelin both raise growth hormone, and that is most of what they have in common. One is a fragment of a human hormone, isolated from tumour tissue in 1982 and approved as a prescription medicine in the United States for nearly two decades. The other is a five-residue molecule designed in a pharmaceutical laboratory in the 1990s, built partly from amino acids that do not occur in human proteins, and with no approved drug product identified anywhere.

This guide sets the two side by side: what each one is, the receptor each acts on, their very different regulatory histories, what the research supports for each class, and what no study has ever compared.

Sermorelin: a fragment of a human hormone

Growth hormone-releasing hormone was one of the last major hypothalamic hormones to be identified, and it was found by an unusual route: not in the brain, but in tumours. In 1982 two groups independently isolated it from pancreatic tumours that had caused acromegaly, the overgrowth syndrome produced by excess growth hormone. Roger Guillemin, Paul Brazeau and colleagues at the Salk Institute in California published their isolation in Science; Jean Rivier, Joachim Spiess and Wylie Vale, also at the Salk Institute, published theirs in Nature with Michael Thorner, and the sequence analysis appeared in Biochemistry the same year.

Attention quickly moved to the molecule’s business end. By 1984, Lance and colleagues were publishing on “super-active analogs of growth hormone-releasing factor (1-29)-amide”, the first 29 residues with an amidated tail. Sermorelin is that fragment: DrugBank describes it as “the acetate salt of an amidated synthetic 29-amino acid peptide” designated GRF 1-29 NH₂, corresponding to the amino-terminal segment of native human GHRH, with a molecular weight near 3,358 g/mol. It binds the GHRH receptor, the same receptor the natural hormone uses.

Ipamorelin: a designed pentapeptide

Ipamorelin came from the opposite direction: not from isolating a natural hormone, but from a chemistry programme refining a class of synthetic compounds. The FDA records that the free base was “first synthesized by researchers at Novo Nordisk in the mid-1990s” and that ipamorelin “was first identified in 1998”, the year Kirsten Raun and colleagues published “Ipamorelin, the first selective growth hormone secretagogue”.

The word “selective” described what it avoided. Earlier growth hormone-releasing peptides, GHRP-6 and GHRP-2 among them, also pushed up ACTH and cortisol. In the 1998 work, ipamorelin did not raise those two hormones even at exposures more than 200 times those needed for its growth hormone effect, and the authors concluded it was “the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH”.

Its structure reflects its synthetic origin. Only two of the five residues, histidine and lysine, are standard amino acids in their natural form. The chain begins with Aib, alpha-aminoisobutyric acid, which no human protein contains, and includes two D-amino acids — mirror images of the natural L-forms. Our guides to amino acid codes and D-amino acids explain the notation, and this unusual composition turns out to matter when verifying a sample, as set out below.

Ipamorelin was taken into human trials, including a phase 2 study for postoperative ileus, the temporary bowel shutdown after abdominal surgery. Beck and colleagues reported in 2014 that it missed its primary endpoint, and the FDA, citing a 2020 review, records that “due to these disappointing results, its development was discontinued”.

Two receptors, one pathway

Growth hormone comes from somatotroph cells in the anterior pituitary, under two opposing hypothalamic signals: GHRH, which stimulates, and somatostatin, which restrains. Sermorelin enters that system as GHRH does, at the GHRH receptor. Ipamorelin enters elsewhere: the FDA describes its action as “primarily via activation of ghrelin receptors in GHRH-positive neurons in the hypothalamus”, from where it “stimulates growth hormone release from the anterior pituitary”. Our guide to how peptide receptors work covers the receptor family both belong to, and our ghrelin guide covers the natural hormone ipamorelin imitates.

What both share, and what distinguishes them from recombinant growth hormone, is that they act upstream. In a 2018 review of growth hormone secretagogues, Sigalos and Pastuszak note that these compounds “promote pulsatile release of GH that is subject to negative feedback”, whereas complications associated with exogenous growth hormone may arise from “the bypass of regulatory feedback mechanisms”. The body’s own brakes, somatostatin and IGF-1 feedback among them, stay in the circuit.

It is worth being precise here, because a common online claim is that ghrelin-receptor agonists work by switching somatostatin off. The review above says close to the opposite: that this class stimulates growth hormone without disturbing the normal feedback mechanisms that include somatostatin and IGF-1. Treat the somatostatin-suppression story as unestablished.

Side by side

Two regulatory histories

Sermorelin’s path through the US system is documented in detail, and it is the single biggest difference between these two compounds.

1. 28 December 1990The FDA approves Geref Diagnostic, indicated for “evaluating the ability of the somatotroph of the pituitary gland to secrete growth hormone”.
2. 26 September 1997A second approval covers Geref for the treatment of idiopathic growth hormone deficiency in children with growth failure.
3. 2008The manufacturer files discontinuation letters for both products.
4. 18 June 2009The FDA withdraws approval of both applications. It later determined that the products “were not withdrawn for reasons of safety or effectiveness”.

That last point is worth stating carefully, because it is often overstated in both directions. The FDA’s finding is that safety and effectiveness were not the reason for withdrawal. The notice does not give a product-specific reason, so descriptions of it as purely a “business decision” are an inference rather than something the FDA stated.

Ipamorelin has no equivalent history. The FDA records that “there are no FDA-approved drug products containing ipamorelin (free base) or ipamorelin acetate”, and that a search of foreign pharmacopoeias and registries “did not show any monograph listings”. In 2024 an FDA briefing document for its Pharmacy Compounding Advisory Committee concluded that the evaluation criteria weighed against adding ipamorelin to the list of bulk substances usable in compounding, citing unresolved immunogenicity risk from impurities and aggregates, limited nonclinical toxicity data, and that “FDA has not identified data to support the effectiveness”.

What else the secretagogue class does

Ghrelin’s best-known role is in appetite, and that carries over to compounds acting at its receptor. The 2018 review notes that this class “may stimulate appetite”, and reports that GHRP-2 “significantly increased ad libitum food intake in a dose-dependent manner” in a human study. That finding belongs to GHRP-2 rather than to ipamorelin specifically, and ipamorelin’s selectivity claim concerned ACTH and cortisol, not appetite.

The gut-motility idea was the one tested most directly, and it is instructive. Ipamorelin’s phase 2 programme in postoperative ileus was built on the expectation that a ghrelin mimetic would get the bowel moving again after surgery. The trial missed its primary endpoint, which is the clearest available answer about that particular effect in people.

What no study has compared

There is no published head-to-head trial of sermorelin against ipamorelin. We searched for one and found only reviews, reference entries and unrelated work. That matters for how any comparison, including this one, should be read: everything above comes from separate studies, run at different times, in different populations, with different endpoints and different measurement methods.

So statements that one is “stronger” or “better tolerated” than the other are not resting on a trial that tested the question. Our guide to how to read a peptide study covers why cross-study comparisons mislead, and clinical trial phases explained covers what each stage of evidence can support.

Verifying each one

The two peptides raise genuinely different analytical questions, and a certificate that is adequate for one may not be for the other.

Ipamorelin: chirality is the issue. The FDA’s own evaluation notes that ipamorelin contains “non-proteinogenic amino acids, including Aib (Aminoisobutyric acid) and Nal (naphthylalanine)” and that “the exact amino acid sequence and chirality are critical determinants of the affinity” of this class for ghrelin receptors. Here is the problem: a D-amino acid has exactly the same mass as its L-form, and Aib has the same mass as other small amino acids it could be confused with. Mass spectrometry therefore cannot confirm that the D-residues are D, or that Aib is Aib. Confirming that takes chiral analysis or a comparison against a reference standard on a method that resolves the alternatives. The FDA also observed that for the free base there is “limited or no information on the impurity limits/testing results” and that it “is not well-characterized from the physical and chemical characterization perspective” — a reason to read a supplier’s documentation closely rather than assume a mass match settles identity.

Sermorelin: length is the issue. A 29-residue peptide assembled one residue at a time goes through many more synthesis steps than a pentapeptide, and each step is an opportunity for a by-product. What matters on the report is therefore a chromatogram showing a well-resolved main peak, rather than a bare percentage that could conceal something eluting close to it. Our guides to reading an HPLC chromatogram, reading a mass spectrum and how research peptides are made cover the method and its limits, and the COA guide covers what a certificate should contain.

SermorelinGHRH(1-29) amideView product IpamorelinSelective pentapeptide secretagogueView product CJC-1295 with DACLong-acting GHRH analogueView product CJC-1295 + IpamorelinBoth classes in one vialView product

Frequently asked questions